FindTrial
Sign In

Saline containing 1% Human serum albumin（solution without UC-MSCs）

BIOLOGICAL2 trials

Sponsors

Beijing 302 Hospital

Conditions

Corona Virus Disease 2019(COVID-19)Decompensated Cirrhosis

Phase 2

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)
CompletedNCT04288102
Beijing 302 HospitalCorona Virus Disease 2019(COVID-19)
Start: 2020-03-05End: 2020-07-09Updated: 2020-08-19
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
NCT05121870
Beijing 302 HospitalDecompensated Cirrhosis
Start: 2021-09-01End: 2023-12-31Target: 240Updated: 2021-11-16

Related Papers

Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial
Stem Cell Research & Therapy2025-02-254 citations
Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial.
2023-05-0520 citations
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.
2021-12-2581 citations
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
2021-02-10188 citations